Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-Arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer

Next Previous
Search
Trial Profile

A 2-Arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pelareorep (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium
    • 22 Jan 2020 According to an Oncolytics Biotech media release, additional data from this study will be announced following the poster presentation at the 2020 Gastrointestinal Cancers Symposium sponsored by ASCO.
    • 22 Jan 2020 According to an Oncolytics Biotech media release, the abstract to be presented at the 2020 Gastrointestinal Cancers Symposium sponsored by ASCO has been published. The abstract was co-authored by Dr. Anne Noonan and Dr. Tanios Bekaii-Saab.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top